Arrowstreet Capital
IMCR icon

Arrowstreet Capital’s Immunocore IMCR Stock Holding History

Arrowstreet Capital’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,579
Closed -$1.17M – 1972
2025
Q4 		$1.17M Buy
+33,579
New +$1.19M ﹤0.01% 1521
2023
Q1 		– Sell
-4,718
Closed -$269K – 1423
2022
Q4 		$269K Buy
+4,718
New +$266K ﹤0.01% 1230

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Arrowstreet Capital's IMCR Position: Q1 2026 in Review

Arrowstreet Capital sold out of Immunocore (IMCR) in Q1 2026, closing a stake of 33,579 shares — an estimated $1.17M sold.

Arrowstreet Capital first reported a position in IMCR in Q4 2022 and held it in 2 quarters. The position peaked at $1.17M in Q4 2025. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Arrowstreet Capital reported no remaining Immunocore position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 33,579 Immunocore shares in Q1 2026, an estimated $1.17M.
  • Arrowstreet Capital first reported a position in Immunocore in Q4 2022 and held it in 2 quarters.
  • Arrowstreet Capital's Immunocore position peaked at $1.17M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.